Zydus Cadila has received the final approval from the US Food and Drug Administration (USFDA) to market Cisatracurium Besylate Injection USP 10 mg (base)/5 mL (2 mg/mL) and 200 mg (base)/20 mL (10 mg/mL) Single-Dose Vials (Preservative-free)(US RLD- Nimbex).
This medication is used to relax the muscles. It works by blocking the signals between one’s nerves and one’s muscles. This medicine is given before general anaesthesia in preparing for surgery. It will be manufactured at Liva Pharmaceuticals, a wholly-owned subsidiary company of Cadila Healthcare.
The group now has 275 approvals and has so far filed over 360 ANDAS since the commencement of the filing process in FY 2003-04.
Cadila Healthcare is an India-based pharmaceutical company. The company's subsidiaries include Zydus Wellness, Liva Pharmaceuticals, Biochem Pharmaceutical Industries, Zydus Technologies, German Remedies, Dialforhealth India, Dialforhealth Unity and Dialforhealth Greencross, among others.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1847.30 |
| Dr. Reddys Lab | 1293.25 |
| Cipla | 1347.70 |
| Zydus Lifesciences | 938.90 |
| Lupin | 2377.90 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: